Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

IPO/Stock Watch

Market trends, bell-weather stocks, filings and IPOs...

Loncar Launches China BioPharma ETF on NASDAQ Exchange
Ascletis and BeiGene Trade Lower Following Hong Kong IPOs
Shanghai Junshi Files for $500 Million HK IPO; Has $2 Billion Valuation
Ascletis Completes $400 Million IPO; Valuation is $2 Billion
BeiGene Raised $900 Million in Hong Kong Debut Offering
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event

Device China 2018
September 8-9, 2018